{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:17:07Z","timestamp":1787854627973,"version":"build-2784847793"},"reference-count":48,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000948","name":"Pfizer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Homologous recombination repair (HRR) gene alterations are key drivers of disease in prostate cancer. This has led to great interest in HRR targeted therapies, particularly polyadenosine diphosphate\u2010ribose inhibitors (PARPi), in the treatment of metastatic castrate resistant prostate cancer (mCRPC). HRR alterations are typically early events in prostate cancer tumorigenesis. As a result, clinical trials are investigating the efficacy of PARPi therapy in metastatic hormone sensitive prostate cancer (mHSPC). Recently, based on positive results from the phase III AMPLITUDE trial, niraparib was approved in the United States for the treatment of patients with\n                    <jats:italic>BRCA2<\/jats:italic>\n                    \u2010mutated mHSPC. Positive results have also recently been obtained from the phase III TALAPRO\u20103 trial; talazoparib added to enzalutamide led to significantly better imaging\u2010based progression\u2010free survival than placebo plus enzalutamide among patients with mHSPC harboring HRR alterations. Furthermore, international guidelines now recommend HRR mutation testing for patients with mHSPC. However, in Australia there is currently no reimbursement for HRR mutation testing in the mHSPC setting. Here, we review the current knowledge of the clinical relevance of HRR alterations and highlight the benefits of genomic profiling of hormone\u2010sensitive disease prior to the development of castrate resistant disease.\n                  <\/jats:p>","DOI":"10.1111\/ajco.70169","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:18:22Z","timestamp":1787851102000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing Homologous Recombination Repair Mutation Testing in Prostate Cancer in Australia: Shifting the Focus to Hormone Sensitive Prostate Cancer"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-5622","authenticated-orcid":false,"given":"Arun A.","family":"Azad","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7500-5899","authenticated-orcid":false,"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"},{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-680X","authenticated-orcid":false,"given":"Edmond M.","family":"Kwan","sequence":"additional","affiliation":[{"name":"Eastern Health Clinical School Monash University  Melbourne Australia"},{"name":"Cancer Services, Eastern Health  Melbourne Australia"},{"name":"Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":false,"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[{"name":"Kinghorn Cancer Centre, St Vincent's Hospital  Sydney Australia"},{"name":"Garvan Institute of Medical Research  Sydney Australia"},{"name":"School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2"},{"key":"e_1_2_11_3_1","unstructured":"\u201cProstate Cancer in Australia Statistics \u201dCancer Australia accessed February 20 2026 https:\/\/www.canceraustralia.gov.au\/cancer\u2010types\/prostate\u2010cancer\/prostate\u2010cancer\u2010australia\u2010statistics."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2014.35"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.06.003"},{"key":"e_1_2_11_6_1","unstructured":"\u201cNCCN Guidelines\u2014Prostate Cancer (Version 5) \u201dNational Comprehensive Cancer Network https:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?id=1459."},{"key":"e_1_2_11_7_1","unstructured":"P.Cornford D.Tilki R. C. N.van denBergh et\u00a0al. EAU\u2013EANM\u2013ESTRO\u2013ESUR\u2013ISUP\u2013SIOG Guidelines on Prostate Cancer (European Association of Urology 2025)."},{"issue":"5","key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.eururo.2025.12.021","article-title":"ARCHES 5\u2010Year Survival With Enzalutamide Plus Androgen\u2010Deprivation Therapy in Metastatic Hormone\u2010Sensitive Prostate Cancer Patients","volume":"89","author":"Armstrong A. J.","year":"2026","journal-title":"European Urology"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00063-3"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"v328","DOI":"10.1093\/annonc\/mdz248.004","article-title":"847PD\u2014Central, Prospective Detection of Homologous Recombination Repair Gene Mutations (HRRm) in Tumour Tissue From >4000 Men With Metastatic Castration\u2010Resistant Prostate Cancer (mCRPC) Screened for the PROfound Study","volume":"30","author":"Bono J. S.","year":"2019","journal-title":"Annals of Oncology"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"issue":"6","key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to Advanced Prostate Cancer: AUA\/SUO Guideline","volume":"209","author":"Lowrance W.","year":"2023","journal-title":"Journal D Urologie"},{"key":"e_1_2_11_13_1","unstructured":"\u201cPharmaceutical Benefits Scheme Olaparib \u201dAustralian Government\u2014Department of Health Disability and Ageing accessed March 11 2026 https:\/\/www.pbs.gov.au\/medicine\/item\/11528R\u201011539H\u201012157W\u201012161C\u201012913P\u201012929L."},{"key":"e_1_2_11_14_1","unstructured":"\u201cPharmaceutical Benefits Scheme Talazoparib \u201dAustralian Government\u2014Department of Health Disability and Ageing accessed March 11 2026 https:\/\/www.pbs.gov.au\/medicine\/item\/14683T."},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"S993","DOI":"10.1016\/j.annonc.2023.09.2783","article-title":"1835P A Prospective Study to Determine the Prevalence of DNA Repair Defects in Patients (pts) With Advanced Prostate Cancer (PC)","volume":"34","author":"Sandhu S. K.","year":"2023","journal-title":"Annals of Oncology"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.534"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.01.011"},{"issue":"5","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.5489\/cuaj.9240","article-title":"2025 Canadian Urological Association\u2013Canadian Uro\u2010Oncology Group Guideline: Metastatic Castration\u2010Naive and Castration\u2010Sensitive Prostate Cancer (Update)","volume":"19","author":"So A. I.","year":"2025","journal-title":"Canadian Urological Association Journal"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506859"},{"issue":"3","key":"e_1_2_11_20_1","doi-asserted-by":"crossref","DOI":"10.1172\/JCI200920","article-title":"Exploring the Biology of Metastatic Hormone\u2010Sensitive Prostate Cancer: On the Road to Precision Medicine","volume":"136","author":"Bernard\u2010Tessier A.","year":"2026","journal-title":"Journal of Clinical Investigation"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104738"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132031"},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00029","article-title":"Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making","volume":"1","author":"Abida W.","year":"2017","journal-title":"JCO Precision Oncology"},{"issue":"9","key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2350","article-title":"Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell\u2010Free DNA","volume":"7","author":"Schweizer M. T.","year":"2021","journal-title":"JAMA oncology"},{"issue":"6","key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clgc.2022.06.016","article-title":"The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer","volume":"20","author":"Lee A. M.","year":"2022","journal-title":"Clinical Genitourinary Cancer"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00358"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603144"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5333"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.04.034"},{"issue":"6","key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1200\/JCO.2020.38.6_suppl.182","article-title":"Biomarker Analysis of the Phase III IPATential150 Trial of First\u2010Line Ipatasertib (Ipat) Plus Abiraterone (Abi) in Metastatic Castration\u2010Resistant Prostate Cancer (mCRPC)","volume":"38","author":"Shi Z.","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01146-4"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02105"},{"issue":"9","key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/oncolo\/oyae120","article-title":"TRIUMPH: Phase II Trial of Rucaparib Monotherapy in Patients With Metastatic Hormone\u2010Sensitive Prostate Cancer Harboring Germline Homologous Recombination Repair Gene Mutations","volume":"29","author":"Markowski M. C.","year":"2024","journal-title":"Oncologist"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"S996","DOI":"10.1016\/j.annonc.2024.08.1682","article-title":"1601P First Results From ZZFIRST: A Randomized Phase II Trial of Enzalutamide (EZ) With or Without Talazoparib (TALA) in Metastatic Hormone\u2010Na\u00efve Prostate Cancer (mHNPC)","volume":"35","author":"Mateo J.","year":"2024","journal-title":"Annals of Oncology"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03961-8"},{"issue":"4","key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Castration\u2010Resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial","volume":"8","author":"Chi K. N.","year":"2025","journal-title":"European Urology Oncology"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.06.009"},{"key":"e_1_2_11_38_1","unstructured":"\u201cFDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2\u2010Mutated Metastatic Castration\u2010Sensitive Prostate Cancer \u201dUS Food and Drug Administration accessed March 13 2026 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010niraparib\u2010and\u2010abiraterone\u2010acetate\u2010plus\u2010prednisone\u2010brca2\u2010mutated\u2010metastatic\u2010castration."},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2604126"},{"key":"e_1_2_11_40_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMe2605582","article-title":"Precision Intensification in Metastatic Prostate Cancer","volume":"395","author":"McKay R. R.","year":"2026","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"TPS5123","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5123","article-title":"Phase III, Double\u2010Blind, Placebo\u2010Controlled, 2\u2010Cohort, Randomized Study of Saruparib (AZD5305) in Combination With New Hormonal Agents in Patients With Metastatic Castration\u2010Sensitive Prostate Cancer With and Without Homologous Recombination Repair Mutation (EvoPAR\u2010Prostate01)","volume":"42","author":"Chi K. N.","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.01.015"},{"issue":"8","key":"e_1_2_11_43_1","doi-asserted-by":"crossref","first-page":"E276","DOI":"10.5489\/cuaj.9341","article-title":"2025 Canadian Urological Association\u2013Canadian Uro\u2010Oncology Group Guideline: Metastatic Castration\u2010Resistant Prostate Cancer (Update)","volume":"19","author":"Saad F.","year":"2025","journal-title":"Canadian Urological Association Journal"},{"key":"e_1_2_11_44_1","unstructured":"eviQ \u201cProstate Cancer\u2010Panel Testing \u201dCancer Institute NSW accessed February 18 2026 https:\/\/www.eviq.org.au\/cancer\u2010genetics\/adult\/genetic\u2010testing\u2010using\u2010cancer\u2010gene\u2010panels\/3648\u2010prostate\u2010cancer\u2010panel\u2010testing."},{"key":"e_1_2_11_45_1","unstructured":"\u201cMedicare Benefits Schedule\u2014Item 73302 \u201dAustralian Government\u2014Department of Health and Aged Care accessed February 18 2026 https:\/\/www9.health.gov.au\/mbs\/fullDisplay.cfm?type=item&q=73302&qt=item."},{"key":"e_1_2_11_46_1","unstructured":"\u201cMedicare Benefits Schedule\u2014Item 73303 \u201dAustralian Government\u2014Department of Health and Aged Care accessed February 18 2026 https:\/\/www9.health.gov.au\/mbs\/fullDisplay.cfm?type=item&q=73303&qt=ItemID."},{"key":"e_1_2_11_47_1","unstructured":"\u201cMedicare Benefits Schedule\u2014Item 73304 \u201dAustralian Government\u2014Department of Health and Aged Care accessed February 18 2026 https:\/\/www9.health.gov.au\/mbs\/fullDisplay.cfm?type=item&q=73304&qt=item."},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.14150"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.08.004"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70169","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.70169","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:18:28Z","timestamp":1787851108000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.70169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":48,"alternative-id":["10.1111\/ajco.70169"],"URL":"https:\/\/doi.org\/10.1111\/ajco.70169","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"2026-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajco.70169"}}